Status:

TERMINATED

Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome

Lead Sponsor:

Syros Pharmaceuticals

Conditions:

Myelodysplastic Syndromes

Eligibility:

All Genders

18+ years

Phase:

PHASE3

Brief Summary

This study compares the efficacy of Tamibarotene in combination with azacitidine to azacitidine in combination with placebo in participants who are Retinoic Acid Receptor Alpha (RARA) positive, and ne...

Detailed Description

A subset of participants have MDS characterized by an overexpression of the RARA gene. A blood test will be used to identify participants with RARA-positive MDS. Assessment of the RARA biomarker for s...

Eligibility Criteria

Inclusion

  • Key
  • Participants must be RARA-positive based on the investigational assay.
  • Participants must be newly diagnosed with HR-MDS as follows:
  • Diagnosis of MDS according to the World Health Organization (WHO) classification and classified by the Revised International Prognostic Scoring System (IPSS R) risk category as very high, high, or intermediate risk.
  • Participants must have Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤2.
  • Key

Exclusion

  • Participants are suitable for and agree to undergo allogeneic hematopoietic stem cell transplant (HSCT) at the time of screening.
  • Participants who need treatment prior to stem cell transplant can receive treatment on this study and stop the study treatment when they are ready to proceed to transplant.
  • Participants who received prior treatment for MDS with any hypomethylating agent, lenalidomide, chemotherapy or allogeneic HSCT.

Key Trial Info

Start Date :

February 8 2021

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

November 13 2024

Estimated Enrollment :

246 Patients enrolled

Trial Details

Trial ID

NCT04797780

Start Date

February 8 2021

End Date

November 13 2024

Last Update

April 10 2025

Active Locations (128)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 32 (128 locations)

1

University of Arizona

Tucson, Arizona, United States, 85719

2

University of Southern California

Los Angeles, California, United States, 90033

3

University of California, Los Angelas

Los Angeles, California, United States, 90095

4

Yale Cancer Center

New Haven, Connecticut, United States, 06510